(A) Effects of KMT2D silencing on the global levels of
histone H3K4 mono-, di- and tri-methylation using IB analysis. Numbers in
parentheses denote the average-fold change of the ratio H3K4me1, H3K4me2,
orH3K4me3:H3 total protein in KMT2D-silenced cells versus
siC#1-treated cells (set as default 1). (B) Enrichment scores
comparing the read density conditions for each set of peak regions are shown in
the jittered boxplots. The enrichment values were tested with the Mann-Whitney U
test (P<.001). (C) Overlap of H3K4me3 peaks
upon KMT2D suppression using 2 different siRNAs. (D) Effect of
KMT2D silencing on the genomic distribution of H3K4me3
peaks in MIA PaCa-2 cells. Pie chart indicates the enriched H3K4me3 peaks in
negative siRNA versus siKMT2D#2 treated cells. (E) Distribution of
H3K4 tri-methylation mark around TSS. (F) GO terms associated with
H3K4me3 binding sites were determined as follows; ChlP-seq peaks found in siC#1
treated cells versus peaks found in cells treated with siKMT2D#2 were associated
with the nearest ENSEMBL transcript and processed using David (v6.7) tools. The
data presented is log transformed P value of GO terms found to be enriched in
the tested group of genes. (G) Heatmap showing the differentially
expressed genes in MIA PaCa-2 cells upon KMT2D suppression.
Data was filtered using a P value cutoff of .05 and a fold
change cut-off of 2.0. Clustering dendrograms show the relative expression
values according to the following coloring scheme: red = high, black=moderate,
green=low. (H) List of metabolism-associated canonical pathways
derived from Ingenuity Pathway Analysis (IPA) GO algorithms for the
KMT2D-regulated genes (from Figure 3G).
-log (P value) is measured by the bar length, while R refers to the number of
molecules from the dataset that map to the pathway listed divided by the total
number of molecules that map to the pathway from within the IPA knowledge base.
(I) OCR/ECAR curves for KMT2D stably-transfected pancreatic
cancer cells (Seahorse technology). R, Ratio; Oligo,
Oligomycin; FCCP, Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone; RM,
Rotenone/Myxothiazol.